# A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

> **NCT06658535** · PHASE1 · RECRUITING · sponsor: **NuvOx LLC** · enrollment: 18 (estimated)

## Conditions studied

- Mild Respiratory Distress

## Interventions

- **DRUG:** dodecafluoropentane (0.025 mL/kg)
- **DRUG:** dodecafluoropentane (0.032 mL/kg)
- **DRUG:** dodecafluoropentane (0.050 mL/kg)

## Key facts

- **NCT ID:** NCT06658535
- **Lead sponsor:** NuvOx LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06658535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06658535, "A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06658535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*